Construction of a lentiviral vector overexpressing fibronectin type III domain containing 5 to inhibit apoptosis of endothelial cells

doi:10.12307/2022.928

Abstract

Abstract: BACKGROUND: Fibronectin type III domain containing 5 (FNDC5) is a protein molecule that regulates glycolipid metabolism, regulates cell apoptosis and participates in the inhibition of atherosclerosis.
OBJECTIVE: By constructing a lentiviral vector overexpressing FNDC5 for transfecting human umbilical vein endothelial cells, to verify the effect of FNDC5 in regulating endothelial cell apoptosis.
METHODS: The lentiviral vector overexpressing FNDC5 was constructed. Human umbilical vein endothelial cells in logarithmic growth phase were cultured and divided into three groups: blank group was not transfected with lentivirus, control group was transfected with an empty vector lentivirus without FNDC5, and experimental group was transfected with the lentiviral vector overexpressing FNDC5. At 7 days after transfection, RT-PCR and western blot were used to detect the mRNA and protein expression of FNDC5. After 7 days of transfection, oxidized low-density lipoprotein solution was added to the three groups of cells, and the cell viability was determined by cell counting kit-8 method, and cell apoptosis was detected by Hoechst 33342/PI double staining and flow cytometry.
RESULTS AND CONCLUSION: The mRNA and protein expressions of FNDC5 in the experimental group were higher than those in the blank and control groups (P < 0.05). Cell counting kit-8 test results showed that the cell viability in the experimental group was higher than that in the blank and control group at 1 and 2 hours after addition of oxidized low-density lipoprotein (P < 0.05). However, there was no significant difference in the cell viability between the three groups at 4 hours after addition of oxidized low-density lipoprotein (P > 0.05). Flow cytometric results showed that the apoptotic rate was lower in the experimental group than the blank and control group at 24 hours after addition of oxidized low-density lipoprotein (P < 0.05). Hoechst 33342/PI double staining results showed that the number of apoptotic cells in experimental group was less than that in the blank and control groups. To conclude, overexpression of FNDC5 could inhibit the apoptosis of human umbilical vein endothelial cells.

Key words: fibronectin type III domain containing 5, lentivirus, transfection, human umbilical vein endothelial cells, apoptosis, atherosclerosis

CLC Number:

Ou Hangjun, Zhao Guangjian, Pan Yujia, Gong Caiwei, Zhao Quanwei, Liu Danan. Construction of a lentiviral vector overexpressing fibronectin type III domain containing 5 to inhibit apoptosis of endothelial cells[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(2): 216-222.

Figures/Tables 5

References

[1] ZhAO D, LIU J, WANG M, ZHANG X, et al. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203-212.
[2] BARQUERA S, PEDROZA-TOBIAS A, MEDINA C, et al. Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease. Arch Med Res. 2015;46(5):328-338.
[3] KATZIR I, ADLER M, KARIN O, et al. Senescent cells and the incidence of age-related diseases. Aging Cell. 2021;20(3):e13314.
[4] HOPKINS PN. Molecular biology of atherosclerosis. Physiol Rev. 2013; 93(3):1317-1542.
[5] ROSS R, AGIUS L. The process of atherogenesis--cellular and molecular interaction: from experimental animal models to humans. Diabetologia. 1992;35 Suppl 2:S34-S40.
[6] GEOVANINI GR, LIBBY P. Atherosclerosis and inflammation: overview and updates. Clin Sci (Lond). 2018;132(12):1243-1252.
[7] ZHU Y, XIAN X, WANG Z, et al. Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules. 2018; 8(3):80.
[8] WOLF D, LEY K. Immunity and Inflammation in Atherosclerosis. Circ Res. 2019;124(2):315-327.
[9] BÄCK M, YURDAGUL A JR, TABAS I, et al. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16(7):389-406.
[10] ZHU D, WANG H, ZhANG J, et al. Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. J Mol Cell Cardiol. 2015;87:138-147.
[11] GIMBRONE MA JR, GARCÍA-CARDEÑA G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016;118(4):620-636.
[12] XU S, ILYAS I, LITTLE PJ, et al. Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol Rev. 2021;73(3):924-967.
[13] BOSTRÖM P, WU J, JEDRYCHOWSKI MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463-468.
[14] Askari H, Rajani SF, Poorebrahim M, et al. A glance at the therapeutic potential of irisin against diseases involving inflammation, oxidative stress, and apoptosis: An introductory review. Pharmacol Res. 2018;129:44-55.
[15] PERAKAKIS N, TRIANTAFYLLOU GA, FERNÁNDEZ-REAL JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017;13(6):324-337.
[16] WANG J, ZHAO YT, ZHANG L, et al. Irisin Improves Myocardial Performance and Attenuates Insulin Resistance in Spontaneous Mutation (Leprdb ) Mice. Front Pharmacol. 2020;11:769.
[17] Gouveia MC, Vella JP, Cafeo FR, et al. Association between irisin and major chronic diseases: a review. Eur Rev Med Pharmacol Sci. 2016;20(19):4072-4077.
[18] Zhang Y, Song H, Zhang Y, et al. Irisin Inhibits Atherosclerosis by Promoting Endothelial Proliferation Through microRNA126-5p. J Am Heart Assoc. 2016;5(9):e004031.
[19] Zhang X, Hu C, Wu HM, et al. Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target. Acta Pharmacol Sin. 2021;42(9):1390-1400.
[20] Byun K, Lee S. The Potential Role of Irisin in Vascular Function and Atherosclerosis: A Review. Int J Mol Sci. 2020;21(19):7184.
[21] 何青松,刘大男,谭娟.鸢尾素对高脂饮食诱导ApoE~(-/-)小鼠动脉粥样硬化形成的影响及其机制[J].山东医药,2020,60(22):39-43.
[22] 何青松,刘大男,谭娟.冠心病患者血清鸢尾素水平变化观察[J].山东医药,2020,60(6):69-71.
[23] 谭娟,刘大男,何青松,等.鸢尾素对载脂蛋白E基因敲除小鼠动脉粥样硬化的影响[J].中国动脉硬化杂志,2017,25(8):773-777.
[24] Lu J, Xiang G, Liu M, et al. Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice. Atherosclerosis. 2015;243(2):438-448.
[25] Zang YH, Chen D, Zhou B, et al. FNDC5 inhibits foam cell formation and monocyte adhesion in vascular smooth muscle cells via suppressing NFκB-mediated NLRP3 upregulation. Vascul Pharmacol. 2019;121:106579.
[26] Zheng G, Li H, Zhang T, et al. Irisin protects macrophages from oxidized low density lipoprotein-induced apoptosis by inhibiting the endoplasmic reticulum stress pathway. Saudi J Biol Sci. 2018;25(5): 849-857.
[27] 覃铮,刘大男,肖金翠,等.FNDC5过表达慢病毒载体的构建及稳定转染THP-1细胞系[J].重庆医科大学学报,2020,45(2):212-216.
[28] 王向,韦朝俊,王尧,等.构建过表达FNDC5慢病毒载体抑制平滑肌细胞的增殖与迁移[J].中国组织工程研究,2021,25(35):5670-5675.
[29] ZHANG Y, MU Q, ZHOU Z, et al. Protective Effect of Irisin on Atherosclerosis via Suppressing Oxidized Low Density Lipoprotein Induced Vascular Inflammation and Endothelial Dysfunction. PLoS One. 2016;11(6):e0158038.
[30] DUAN H, ZHANG Q, LIU J, et al. Suppression of apoptosis in vascular endothelial cell, the promising way for natural medicines to treat atherosclerosis. Pharmacol Res. 2021;168:105599.
[31] PAONE S, BAXTER AA, HULETT MD, et al. Endothelial cell apoptosis and the role of endothelial cell-derived extracellular vesicles in the progression of atherosclerosis. Cell Mol Life Sci. 2019;76(6):1093-1106.
[32] TAWAKOL A, ABOHASHEM S, ZUREIGAT H. Imaging Apoptosis in Atherosclerosis: From Cell Death, A Ray of Light. J Am Coll Cardiol. 2020;76(16):1875-1877.
[33] Li R, Mittelstein D, Fang K, et al. Angiopoeitin-2 modulates Survivin expression in OxLDL-induced endothelial cell apoptosis. Biochem Biophys Res Commun. 2012;417(1):619-622.
[34] CChiang CY, Ligunas GD, Chin WC, et al. Efficient Nonviral Stable Transgenesis Mediated by Retroviral Integrase. Mol Ther Methods Clin Dev. 2020;17:1061-1070.
[35] Kuroda H, Kutner RH, Bazan NG, et al. Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J Virol Methods. 2009;157(2):113-121.
[36] Buchholz CJ, Friedel T, Büning H. Surface-Engineered Viral Vectors for Selective and Cell Type-Specific Gene Delivery. Trends Biotechnol. 2015;33(12):777-790.
[37] Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4(5):346-358.
[38] Di Pasquale E, Latronico MV, Jotti GS, et al. Lentiviral vectors and cardiovascular diseases: a genetic tool for manipulating cardiomyocyte differentiation and function. Gene Ther. 2012;19(6): 642-648.
[39] Mai S, Grugni G, Mele C, et al. Irisin levels in genetic and essential obesity: clues for a potential dual role. Sci Rep. 2020;10(1):1020.
[40] Zhang J, Valverde P, Zhu X, et al. Exercise-induced irisin in bone and systemic irisin administration reveal new regulatory mechanisms of bone metabolism. Bone Res. 2017;5:16056.
[41] Mazur-Bialy AI, Pocheć E, Zarawski M. Anti-Inflammatory Properties of Irisin, Mediator of Physical Activity, Are Connected with TLR4/MyD88 Signaling Pathway Activation. Int J Mol Sci. 2017; 18(4):701.
[42] Mazur-Bialy AI, Kozlowska K, Pochec E, et al. Myokine irisin-induced protection against oxidative stress in vitro. Involvement of heme oxygenase-1 and antioxidazing enzymes superoxide dismutase-2 and glutathione peroxidase. J Physiol Pharmacol. 2018;69(1):117-125.
[43] Winn RK, Harlan JM. The role of endothelial cell apoptosis in inflammatory and immune diseases. J Thromb Haemost. 2005;3(8): 1815-1824.